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Highlights 
 Synthesis of 23 novel deshydroxy bicalutamide derivatives. 
 Identification of novel and potent double branched AR antagonists. 
 Enhanced anticancer activity against PC compared to bicalutamide and enzalutamide. 
 Strong downregulation of PSA expression in qPCR analysis of LnCaP cell line. 
 Molecular modelling provides a rational explanation of the SAR observed. 
Abstract  
Deshydroxy propioanilides were synthesised by Michael addition reaction between substituted 
thiophenols onto four different phenylacrylamide derivatives to give twenty-four novel deshydroxy 
bicalutamide derivatives lacking the central hydroxyl group. The antiproliferative activities of these 
compounds were evaluated against human prostate cancer cell lines and eleven compounds showed 
better inhibitory activities (IC50 = 2.67-13.19 uM) compared to bicalutamide (IC50 = 20.44 uM) in LNCaP. 
Remarkably, novel double branched bicalutamide analogues (27 and 28) were isolated as major by-
products and found to have the best activity across three human prostate cancer cell lines (LNCaP, 
VCaP and PC3). The most active compound 28 shows sub-micromolar activity (IC50 = 0.43 uM in LNCaP), 
which represents more than 40-fold improvement over the clinical anti-androgen bicalutamide (IC50 = 
20.44 uM) and a more than 3 fold improvement over enzalutamide (IC50 = 1.36 uM). Moreover, strong 
reduction of PSA expression in LNCaP cells upon treatment with compounds 27, 28 and 33 was 
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observed during qPCR analysis, confirming their AR antagonist activity. Molecular modelling studies 
revealed a novel binding mode of these structurally distinct double branched analogues within the 
ligand binding domain (LBD) of the androgen receptor. 
1. Introduction 
The androgen receptor (AR) is expressed in many cell types and plays critical anabolic and reproductive 
roles in men and women. Androgen receptor (AR) signalling has been found to play crucial functions in 
modulating tumourigenesis and metastasis in several types of cancers including prostate, bladder, 
kidney, lung, breast and liver.1 The initiation and progression throughout the different stages of 
prostate cancer (PC) is uniquely dependent on the androgen receptor (AR) signalling pathway.2,3 
Androgen receptor (AR), like other members of the nuclear receptor family, is comprised of three main 
functional domains: a variable N-terminal domain, a highly conserved DNA-binding domain (DBD) and 
a conserved ligand binding domain (LBD).4 Binding of endogenous hormones; testosterone and 
dihydrotestosterone (DHT) to the LBD induces conformational changes in the AR that results in its 
translocation into the nucleus, interaction with DNA, and modulation of specific gene transcription 
(e.g. prostate specific antigen, PSA).5 Androgen receptor antagonists, so-called anti-androgens, are 
designed to inhibit these processes and are clinically used for the treatment of advanced prostate 
cancer (PC).6,7 Several non-steroidal anti-androgens (NSAA) have been approved for the treatment of 
PC. The first generation NSAAs include flutamide, hydroxyflutamide, nilutamide and bicalutamide 
(Figure 1). They decrease androgenic effects by competitively inhibiting the binding of androgens 
(testosterone and DHT) to the AR and induce conformational change of H12 via steric clashes. However, 
these antiandrogens eventually fail to inhibit the AR with the development of castration resistant 
prostate cancer (CRPC). The development of AR-LBD point mutants (e.g. AR-T877A and AR-W741L) 
upon long term treatment with NSAAs ultimately result in switching these AR antagonists to AR 
agonists leading to the relapse of CRPC, which is a more aggressive form of the disease associated with 
poor prognosis. Similar to the first-generation androgen receptor (AR) antagonists, resistance to the 
new second generation anti-androgens (enzalutamide, apalutamide) are developing in PC patients, 
despite the fact that these drugs have better affinity for the AR.8 Anti-androgen resistance can also be 
triggered by the upregulation of the androgen receptor expression, which promotes signalling from 
low levels of residual hormone.8 More recently, darolutamide (ODM-201, Figure 1) is under evaluation 
in phase 3 clinical trials in patients with non-metastatic CRPC.9 The discovery of new AR antagonists is 
urgently needed to improve anti-androgen efficacy and to avoid cross-resistance with the clinically 
used compounds.  
 
 
Figure 1. Chemical structures of the non-steroidal anti-androgens (NSAA); flutamide, hydroxyflutamide, nilutamide, and 
bicalutamide (first generation), enzalutamide and apalutamide (second generation) and darolutamide (phase III clinical 
trials). 
 
2. Results and discussion 
Unfortunately, resistance to clinical anti-androgens has plagued the development of effective 
therapeutics for advanced prostate cancer (PC). Flutamide and bicalutamide (Figure 1) were first 
generation non-steroidal AR antagonists. However, these antiandrogens lose their activity with time 
upon the development of AR-LBD point mutants (AR-T877A and AR-W741L) triggered by flutamide and 
bicalutamide, respectively. On the other hand, AR-F876L mutation causes enzalutamide and 
apalutamide (ARN-509) to function as AR agonists and confers drug resistance across multiple AR 
models both in vitro and in vivo.10 The X- ray structure of bicalutamide inside the LBD site of the AR - 
W741L mutant, (PDB 1Z95), provides a significant insight into the protein−drug interactions and 
explains the structural basis for the conversion of bicalutamide from AR antagonist into AR agonist. 10, 
11 The binding mode of bicalutamide as an antagonist of the AR-wild type compared to its binding mode 
as an agonist of the AR-W741L mutant is shown in Figure 2. It is observed that helix 12 (H12) has 
changed its position from an open antagonist conformation (AR- wild type, blue) to a closed agonist 
conformation (AR- W741L mutant, green). In the case of the antagonist mode, ring B of bicalutamide 
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is pointing outwards away from Trp741 and towards helix 12, thus preventing AR from adapting the 
closed AR agonist conformation. The loss of the steric bulk of the indolyl side chain of tryptophan741 to 
the smaller size side chain of Leucine741 lead to the elimination of the steric clash and hence the 
incorporation of bicalutamide molecule into the closed activated conformation of AR. 10-12 
 
Figure 2. Proposed structural basis for the conversion of bicalutamide from AR antagonist into AR agonist by the gain-of-
function mutation (W741L); the X-ray structure of bicalutamide (green) inside the closed agonist conformation of AR LBD-
W741L, (green, PDB 1Z95) compared to its binding mode (blue) inside the open antagonist conformation of AR LBD-wt, 
showing ring B orientation to hinder helix 12 from closing to an agonist conformation. 
 
From previous studies, we have learnt that the size and structure of ring B determine the activity of 
the anti-androgen and if possesses the correct volume and orientation, it will prevent the anti-
androgen molecule from being completely confined in the AR-LBD pocket cavity, leaving its bulky 
substituents protruding against helix 12 (H12) and stopping the latter from adopting a position 
essential for coactivator interaction (agonist closed conformation). 10-12  
Previously, we have found that the introduction of 3,5-bis‐trifluoromethyl (3,5-bis-CF3) substituents 
into ring B of bicalutamide, enobosarm and umbelliferone derivatives, has profoundly modified their 
anti-proliferative activity, pharmacokinetic and tissue distribution profiles by providing the geometric 
bulk needed to keep ring B towards Helix 12 while keeping the crucial interactions of the nitrile/nitro 
group of ring A with Arg 752.13-15 Noting that both flutamide and darolutamide (ODM-201) are lacking 
the linker OH group, Figure 1, in this work we studied whether the central hydroxyl group of 
bicalutamide is necessary for maintaining the anti-androgen activity and if the successive increase in 
the bulk size of ring B substituents (from 4-F  4-CF3  3,5-bis-CF3) would compensate for the smaller 
size of the deshydroxy linker (lacking the central OH group). We used four different variations of 
aromatic ring A (Figure 3); all containing the necessary 4-CN or 4-NO2 for the interaction with Arg 752 
in addition to either 2-CF3 or 3-CF3 substituent to understand better the structure activity relationship. 
 
Figure 3. Four different variations of ring A containing 4-CN or 4-NO2 group in addition to either 2-CF3 or 3-CF3 
2.1 Chemistry 
The novel series of deshydroxy propioanilide analogues (29-41) were synthesised in three steps. An 
acylation reaction between the corresponding substituted trifluoromethyl anilines (1-4) with 
methacryloyl chloride (5) in dimethylacetamide (DMA) to obtain phenylmethacrylamide derivatives (6-
9) 16,17 was followed by Michael addition of the corresponding substituted thiophenols (10-13) to 
obtain the thioether intermediates (14-26, 19-56% yield), which were subsequently oxidised to the 
corresponding sulfone derivatives (29-41, 19-95% yield) using 3-chloroperbenzoic acid (mCPBA) 
(Scheme 1). It is worth noting that the thioethers (14-20 and 24-26) were prepared using sodium 
hydride (NaH) in tetrahydrofuran (THF) at room temperature (method A), whereas the thioethers (21-
23) corresponding to the N-(4-cyano-2-(trifluoromethyl)phenyl) methacrylamide (8) were prepared 
using aqueous sodium hydroxide solution and tetrabutylammonium chloride in 1,4-dioxane and reflux 
for 3 hours instead (method B), as the first method did not yield any products.18 The intermediate 
sulphides (15, 16, 20-22) were used directly into the next oxidation step since further purification was 
not feasible. Interestingly, alongside the thioether compounds (15 and 26) we obtained two unusual 
disubstituted (double branched) acrylamide derivatives (27 and 28, respectively) as major by-products 
in an approximate ratio of 2 (double branched 27 and 28) : 1 (single branched 15, 26), scheme 1.  
 
 
Scheme 1. Synthesis of racemic deshydroxy propioanilide derivatives. Reagents and conditions: (i) methacryloyl chloride 5 
(8 equiv), DMA, rt, 3 h; (ii) thiophenol derivatives (10-13, 1.2 equiv), method A: NaH (1.2 equiv), THF, rt, 24 h (6,7,9) or 
method B: NaOH, 1,4-dioxane, tetrabutylammonium chloride reflux 3 hr (8); (iii) mCPBA (1.4 equiv), DCM, rt, 4-6 h. 
 
The mechanism of the formation of the double branched products remains to be fully clarified. All 
compounds were purified by column chromatography and/or recrystallised. The structures of all the 
synthesised compounds were confirmed using analytical and spectroscopic data (1H NMR, 13C NMR, 
19F NMR and mass spectrometry), which were in full accordance with their depicted structures.  
                         
ID R1 R2 R3 X IC50 (uM) 
14 CN 3-CF3 4-F S 8.69 
15 CN 3-CF3 4-CF3 S - 
16 CN 3-CF3 3,5-BisCF3 S - 
17 CN 3-CF3 3-OCF3 S 114.97 
18 NO2 3-CF3 4-F S 27.16 
19 NO2 3-CF3 4-CF3 S 4.41 
20 NO2 3-CF3 3,5-BisCF3 S - 
21 CN 2-CF3 4-F S - 
22 CN 2-CF3 4-CF3 S - 
23 CN 2-CF3 3,5-BisCF3 S 4.57 
24 NO2 2-CF3 4-F S 43.19 
  
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Chemical structure and in vitro anti-proliferative activity (IC50 in M) of single (14-26, 29-41) and double (27, 28) 
branched deshydroxy propioanilide analogues compared to bicalutamide and enzalutamide in the LNCaP cell line. IC50 
values presented are the mean of three independent experiments. 
 
2.2 Cell growth inhibition activity 
The twenty-four novel deshydroxy antiandrogen compounds 14, 17-19, 23-41, were tested for their 
anti-cancer activity as racemic mixtures against human androgen-sensitive prostate cancer cell line 
LNCaP at 9 concentrations in half-log increments up to 100 μM for 96 hours in triplicate. Bicalutamide 
and enzalutamide were used as positive controls. Potency is expressed as absolute IC50 values, 
calculated by non-linear regression analysis. The results summarised in Table 1 indicated that thirteen 
compounds (14, 19, 23, 27, 28, 31-35, 38, 39 and 41) showed better anti-proliferative activity than 
bicalutamide with IC50 values in the range of 0.43-13.19 μM, while the positive controls, bicalutamide 
and enzalutamide exhibited IC50 values of 20.44 and 1.31 μM, respectively. Interestingly, the double 
branched compounds 27 and 28 exhibited significantly potent activity compared to bicalutamide and 
enzalutamide in LNCaP cell line (Table 2). The most active compounds 27, 28 and 33 (Figure 4) were 
selected to be further tested against VCaP and PC3 human prostate cancer cell lines, which represent 
metastatic and more aggressive forms of prostate cancer (CRPC).19 
Compound ID LNCaP IC50 (uM) VCaP IC50 (uM) PC3 IC50 (uM) 
27 1.68 0.13 5.45 
28 0.43 0.18 0.91 
33 2.67 8.21 112.30 
Bicalutamide 20.44 5.96 92.63 
Enzalutamide 1.31 3.66 15.07 
Table 2.  In vitro anti-proliferative activity (IC50 in M) of compounds (33, 27 and 28) compared to bicalutamide and 
enzalutamide in human prostate cancer cell lines; LNCaP, VCaP and PC3 
25 NO2 2-CF3 4-CF3 S 54.33 
26 NO2 2-CF3 3,5-BisCF3 S 43.68 
27 CN 3-CF3 4-CF3 - 1.68 
28 NO2 2-CF3 3,5-BisCF3 - 0.43 
29 CN 3-CF3 4-F SO2 114.74 
30 CN 3-CF3 4-CF3 SO2 57.98 
31 CN 3-CF3 3,5-BisCF3 SO2 6.16 
32 CN 3-CF3 3-OCF3 SO2 13.19 
33 NO2 3-CF3 4-F SO2 2.67 
34 NO2 3-CF3 4-CF3 SO2 3.31 
35 NO2 3-CF3 3,5-BisCF3 SO2 12.23 
36 CN 2-CF3 4-F SO2 137.7 
37 CN 2-CF3 4-CF3 SO2 28.79 
38 CN 2-CF3 3,5-BisCF3 SO2 9.56 
39 NO2 2-CF3 4-F SO2 4.05 
40 NO2 2-CF3 4-CF3 SO2 26.34 
41 NO2 2-CF3 3,5-BisCF3 SO2 3.08 
Bical - - - - 20.44 
Enzal - - - - 1.31 
  
Figure 4. Dose-response relationship of LNCAP cells treated with 0-100 μM of compounds; (27, A), (29, B) or (33, C) (red), 
bicalutamide (green) and enzalutamide (blue) for 96 h. Data is presented as the mean ± SD of three replicates at each 
concentration. 
2.3 Downregulation of PSA Expression in LNCaP Cells  
Prostate specific antigen (PSA) is a serine protease that is synthesised by both normal and malignant 
epithelial cells of the human prostate. The expression of PSA is mainly induced by androgens and 
regulated primarily by the androgen receptor (AR) at the transcriptional level 20,21. The effect of 
compounds 27, 28 and 33 on prostate specific antigen (PSA, an AR-regulated gene) expression was 
analysed using qPCR after incubation of LNCaP cells with 5, 10, 50 and 100 μM of bicalutamide, 
compounds 27, 28 and 33, for 24-hours. The analysis shows that the three compounds 27, 28 and 33 
exhibited dose dependent inhibition of PSA expression with compound 28 showing the best activity 
significantly exceeding that of bicalutamide (Figure 5). The significant reduction of the AR-regulated 
PSA expression in the qPCR analysis, suggests that these compounds have strong AR-antagonist 
activity. 
 Figure 5. The relative change in PSA expression (PSA/HK) in LNCaP cells upon treatment with increasing doses of 
bicalutamide (A), compounds; 27 (B), 28 (C) and 33 (D). HK: housekeeping genes (Bactin and GAPDH) 
 
2.4 Docking studies reveal a structural basis for anti-androgen activity  
Previous X-ray crystallographic studies of androgen receptor have elucidated the structures of the AR 
ligand binding domain (LBD) bound to agonists, and of mutant AR bound to antagonists in an agonist 
like conformation. However, there are no crystal structures of the AR-LBD in an antagonist 
conformation reported so far.22,23 The human progesterone receptor (hPR residues 683-931) has 56% 
primary sequence homology to the hAR (residues 669-918) and 32% of these residues are conservative 
mutations, giving an overall sequence homology of 87%.24 Building on this information, the hPR crystal 
structure [PDB 2OVH]25 was used as a template to build an hAR homology model (HM) using the 
sequence of the hAR in the agonist conformation [PDB 2AMA].26 Applying the default parameters of 
MOE (Molecular Operating Environment - Chemical Computing Group, Montreal, Canada) homology 
modelling module and using the AMBER99 force field, a total of 10 homology models were generated. 
The quality of each model was assessed within MOE, and the best model was chosen for the docking 
studies.  
Computational docking studies were performed to explore the binding modes of the deshydroxy 
propioanilide analogues (14-41) within the AR-LBD binding site. The chemical structures of our 
compounds (14-41) were constructed, rendered and minimized with the MMFF94x force field in MOE. 
Docking simulations were performed using Glide SP in Maestro (Glide, version 9.5, Schrödinger, LLC, 
New York, NY. http://www.schrodinger.com). The putative docking modes of the most active single 
branched deshydroxy propioanilide compounds 41, 34 and 33 (IC50 = 3.08, 3.31 and 2.67 M, 
respectively) are shown in Figure 6 (A-C, respectively). All three compounds show the crucial H-bond 
interaction between their nitro group (4-NO2, ring A) and the guanidine group of the Arg-752 residue. 
Other key interactions of compound 41 include an H-bond between the aromatic ring B (ArH) and 
carbonyl group of Asn 705 and the carbonyl group and Met 742 (Figure 5A). Compound 34 shows an 
additional H-bond between the nitro group (4-NO2, ring A) and the amino group of Gln 711, and another 
H-bond between the amide NH group and the carbonyl group of Leu 704. Also, a H-bond between the 
sulphone group and the side chain of Met 745 residue was observed (Figure 5B). Compound 33 shows 
a hydrogen bond between the aromatic ring A and the side chain of Met 742 residue, and another H-
bond between the sulphone group and the side chain of Met 745 residue.  
 
Figure 6. The predicted binding modes of compounds (41, A), (34, B) and (33, C) inside the hAR-LBD showing H-bond 
interactions with key amino acids; Arg752, Gln711, Met 742, Met 745, Leu704, Thr877 and Asn705. 
 
On the other hand, the docking of the double branched deshydroxy compounds (27 and 28) revealed 
an interesting binding mode where the ring A aryl nitrile (4-CN, 27) and aryl nitro (4-NO2, 28) groups 
form a hydrogen bond with the guanidine group of Arg752 in the AR ligand binding pocket, mimicking 
the interaction between the 3-keto functionality of the hormone dihydrotestesterone (DHT) and the 
androgen receptor. The two branches of ring B occupy simultaneously the two sub-pockets that are 
known to be involved in the binding of bicalutamide and enzalutamide27 which may explain well the 
high potency observed with this type of distinctive scaffold (Figure 7).  
 
Figure 7. The predicted binding modes of bicalutamide (green), enzalutamide (blue) compared to the double-branched 
compounds (pink); 27 (I) and 28 (II) within the hAR-LBD (grey ribbon). Left panel (top) is showing the 2D representation of 
compound 27 (I) and compound 28 (II). 
 
Generally, our SAR analysis of this family of compounds indicates that the lack of the linker hydroxy 
group of the propioanilide scaffold seems to be tolerated in terms of the anti-proliferative activity in 
PC cell lines and in some cases showed enhanced activity compared to bicalutamide; compounds (14, 
19, 23, 27, 28, 31-35, 38, 39 and 41). Compounds 27 and 28 were significantly more potent than both 
bicalutamide and enzalutamide in our models. Docking studies suggest that this enhanced activity can 
be attributed to the steric bulk added by the two branches of the aromatic ring B which occupy both 
the proposed binding pockets of bicalutamide and enzalutamide simultaneously and would provide 
the geometric bulk needed to keep ring B pointing outwards away from Trp741 and towards helix 12, 
thus preventing AR from adapting the AR agonist (closed) conformation (Figure 7). These double 
branched compounds (27 and 28) are distinct from the structures of other nonsteroidal anti-
androgens, which is likely to result in differences in biology and resistance mechanisms. 
3. Conclusion 
 
A series of twenty-four novel deshydroxy bicalutamide analogues (29-41) were synthesised using a 
Michael addition reaction between four different acrylamide derivatives (6-9) and various fluorinated 
thiophenols (10-13) as a key step. Eleven compounds showed anti-proliferative activity (IC50 = 0.43-
13.19 μM) better than bicalutamide (IC50 = 20.44 μM). Interestingly, compounds 27 and 28 exhibited 
very potent activity with IC50 values of 1.68 and 0.43 μM, respectively, which is comparable or better 
than enzalutamide (IC50 = 1.31 μM) in the LNCaP cell line. Further testing for the in vitro anti-
proliferative activity in VCaP and PC3 cell lines showed sub-micromolar activity. Furthermore, 
compounds 27, 28 and 33 showed remarkable reduction of PSA expression in LNCaP cells confirming 
their anti-androgenic activity. Molecular modelling studies indicated that the enhanced anti-androgen 
activity of compounds 27 and 28 appears to be a result of the extra bulk conferred by the two aromatic 
rings B, which ensure the occupation of the two sub-pockets of the AR-LBD involved in the binding 
interaction of bicalutamde and enzalutamide simultaneously. This may forestall the drug resistance 
seen with current clinical anti-androgens. Compounds 27 and 28 have distinctive chemical structure 
and represents promising lead for further development of AR antagonists. Overall, this study provides, 
for the first time, the double-branched configuration into the non-steroidal anti-androgen library and 
lays a foundation for the development of alternative AR antagonist therapies capable of combating 
prostate cancer.  
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4. Experimental section 
4.1 Chemistry 
All chemicals were purchased from Sigma-Aldrich or Alfa Aesar and were used without further 
purification. Thin Layer Chromatography (TLC): pre-coated aluminium backed plates (60 F254, 0.2 mm 
thickness, Merck) were visualized under both short and long wave UV light (254 and 366 nm). Flash 
column chromatography was carried out using silica gel supplied by Fisher (60A, 35-70 m). 1H NMR 
(500 MHz), 13C NMR (125 MHz) and 19F NMR (470 MHz) spectra were recorded on a Bruker Avance 500 
MHz spectrometer at 25 C. Chemical shifts (δ) are expressed in parts per million (ppm) and coupling 
constants (J) are given in hertz (Hz). The following abbreviations are used in the assignment of NMR 
signals: s (singlet), bs (broad singlet); d (doublet), t (triplet), q (quartet), qn (quintet), m (multiplet), dd 
(doublet of doublet), dt (doublet of triplet), td (triple doublet); dq (double quartet), m (multiplet), dm 
(double multiplet). Mass spectrometry was performed as a service through the EPSRC National Mass 
Spectrometry centre (Swansea, UK). 
4.1.1 General method for the preparation of intermediates 6-9 
Methacryloyl chloride 5 (8.4 mL, 85.96 mmol) was added over the course of 10 minutes to a stirring 
solution of the appropriate trifluoromethyl-substituted aniline 1-4 (10.75 mmol) in N, N-
dimethylacetamide (10 mL) at room temperature for 24h. After the reaction was complete, the mixture 
was diluted with ethyl acetate (100 mL), extracted with saturated NaHCO3 solution (2 x 50 mL) then 
cold brine (2 x 50 mL). The combined organic layer was dried over anhydrous Na2SO4 and the solvent 
was removed under reduced pressure. The crude oil residue was purified by flash column 
chromatography eluting with chloroform-ethyl acetate 95:5 v/v to obtain the titled compounds. 
N-(4-cyano-3-(trifluoromethyl)phenyl)methacrylamide (6)16. Yield; 92% 
1H NMR (CDCl3) δ 8.10 (d, J = 2Hz, 1H, ArH), 8.06 (bs, 1H, NH), 8.01 (dd, J = 2, 8.5 Hz, 1H, ArH), 7.81 (d, 
J = 8.5Hz, 1H, ArH), 5.89 (d, J = 1Hz, 1H, CH2), 5.62 (q, J = 1.5Hz, 1H, CH2), 2.10 (dd, J = 0.5, 1.5 Hz, 3H, 
CH3). 19F-NMR: (CDCl3) δ -62.23. 
N-(4-nitro-3-(trifluoromethyl)phenyl)methacrylamide (7) 16. Yield; 80% 
1H-NMR (CDCl3): δ 7.99-7.95 (m, 2H, ArH), 7.93 (d, J = 9 Hz, 1H, ArH), 7.8 (bs, 1H, NH), 5.81 (q, J = 1Hz 
1H, CH2), 5.55 (q, J = 1.5 Hz, 1H, CH2), 2.02 (dd, J = 1, 1.5 Hz, 3H, CH3). 19F-NMR (CDCl3): δ -60.09. 
N-(4-cyano-2-(trifluoromethyl)phenyl)methacrylamide (8) 17. Yield; 88 % 
1H-NMR (CDCl3):  8.69 (d, J= 9 Hz, 1H, ArH), 8.07 (bs, 1H, NH), 7.84 (d, J= 1.5 Hz, 1H, ArH), 7.78 (dd, J= 
2, 9 Hz, 2 Hz, 1H, ArH), 5.83 (q, J = 1 Hz, 1H, CH2), 5.56 (q, J= 1.5 Hz, 1H, CH2), 2.02 (dd, J= 1, 1.5 Hz, 3H, 
CH3). 19F-NMR (CDCl3):  -61.35. 
N-(4-nitro-2-(trifluoromethyl)phenyl)methacrylamide (9) 17 Yield; 94 % 
1H NMR (CDCl3) δ 8.73 (d, J= 9 Hz, 1H, ArH), 8.46 (d, J= 3 Hz, 1H, ArH), 8.37 (dd, J= 9 Hz, 2.5 Hz, 1H, ArH), 
8.17 (bs, 1H, NH), 5.85 (q, J= 0.5 Hz, 1H, CH2), 5.58 (q, J= 1.5 Hz, 1H, CH2), 2.15-2.13 (dd, J= 1, 1.5 Hz, 
1H, CH3). 19F-NMR: (CDCl3)  -61.31. 
4.1.2 General method for the preparation of sulphide intermediates; 
4.1.2.1 Method A: (14-20 and 24-28)  
To a mixture of 60% sodium hydride in mineral oil (94.43 mg, 2.36 mmol) in anhydrous tetrahydrofuran 
(5 mL) at 0°C under anhydrous THF under nitrogen atmosphere, was added dropwise the 
corresponding thiophenol 10-13 (2.05 mmol). This mixture was stirred at room temperature for 20 
minutes. A solution of the appropriate intermediate 6-9 (1.57 mmol in 5 mL anhydrous 
tetrahydrofuran) was added slowly to the thiophenol mixture and stirred at room temperature for 24h. 
The mixture was concentrated under vacuum then diluted with ethyl acetate (30 mL), washed with 
brine (20 mL) and water (30 mL), dried over anhydrous sodium sulfate and concentrated under 
vacuum. The crude residue was purified by column chromatography eluting with chloroform-ethyl 
acetate gradually increasing from 95:5 to 90:10 v/v. 
4.1.2.2 Method B: (21-23) 
The corresponding thiophenol 10-13 (2.05 mmol) was added dropwise to an aqueous sodium 
hydroxide solution (79 mg in 1 ml water) for 15 min at room temperature. Then a solution of compound 
8 (2.05 mmol) in 1,4- dioxan (5 mL) was added at room temperature followed by a catalytic amount of 
tetrabutylammonium bromide. The reaction mixture was refluxed for 3 h and cooled to room 
temperature, followed by addition of 26% aqueous acetic acid. This mixture was extracted with ethyl 
acetate (2 x 200 mL). The ethyl acetate layer was separated, washed with water, and concentrated 
under reduced pressure. The crude residue was purified by column chromatography eluting with 
chloroform-ethyl acetate gradually increasing from 95:5 to 90:10 v/v. 
N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)thio)-2-methylpropanamide (14). Yield; 
50% 
1H-NMR: (CDCl3) δ 8.01 (s, 1H, ArH), 7.90 (d, J = 8.5Hz, 1H, ArH), 7.85 (s, 1H, NH), 7.79 (d, J = 9 Hz, 1H, 
ArH), 7.38 (dd, J = 5.5, 8 Hz, 2H ArH), 7.00 (t, J = 8.5Hz, 2H, ArH), 3.28 (dd, J = 8, 14Hz, 1H, CH2), 3.04 
(dd, J = 5, 13.5Hz, 1H, CH2), 2.64 (sext, J = 7Hz, 1H, CH), 1.37 (d, J = 7Hz, 3H, CH3). 19F-NMR: (CDCl3) δ -
62.23, -114.26, 13C-NMR: (CDCl3) δ 173.59 (C=O), 162.04 (d, 1JC-F = 246.4Hz, ArC), 142.10 (ArC), 135.79 
(ArCH), 133.99 (q, 2JC-F = 32.9Hz, ArC), 132.64 (d, 3JC-F = 8Hz, ArCH), 130.04 (d, 4JC-F = 3.6Hz, ArC), 122.10 
(q, 1JC-F = 272.5Hz, CF3), 121.85 (ArCH), 117.31 (q, 3JC-F = 4.6Hz, ArCH), 116.32 (d, 2JC-F = 21.8Hz, ArCH), 
115.63 (CN), 104.08 (ArC), 42.62 (CH), 38.57 (CH2), 17.66 (CH3). HRMS calcd for C18H14F4N2OS [M+H], 
383.0836; found, 383.0836. 
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-3-((3-(trifluoromethoxy)phenyl)thio) propanamide 
(17). Yield; 47% 
1H-NMR: (CDCl3) δ 8.54 (s, 1H, NH), 8.08 (d, J = 1.5Hz, 1H, ArH), 7.94 (dd, J = 2, 8.5Hz, 1H, ArH), 7.74 
(d, J = 8.5Hz, 1H, ArH), 7.27 (m, 2H, ArH), 7.16 (s, 1H, ArH), 6.99 (d, J = 7.5Hz, 1H, ArH), 3.35 (dd, J = 9, 
13.5Hz, 1H, CH2), 3.09 (dd, J = 5.5, 13.5Hz, 1H, CH2), 2.83 – 2.74 (m, 1H, CH), 1.40 (d, J = 7Hz, 3H, CH3). 
19F-NMR: (CDCl3) δ -57.86, -62.34, 13C-NMR: (CDCl3) δ 173.93 (C=O), 149.50 (ArC), 142.58 (ArC), 
138.06 (ArC), 135.73 (ArCH), 133.91 (q, 2JC-F = 32.4Hz, ArC), 130.21(ArCH), 127.10 (ArCH), 122.12 (q, 
1JC-F = 272.5Hz, OCF3), 121.93 (ArCH), 121.11 (ArCH), 120.33 (q, 1JC-F = 253.5Hz, CF3), 118.53 (ArCH), 
117.42 (q, 3JC-F = 4.8Hz, ArCH), 115.89 (CN), 103.41 (ArC), 42.49 (CH), 36.72 (CH2),  17.76 (CH3). HRMS 
calcd for C19H14F6N2O2S, 449.0753; found, 449.0752 [M+H], 466.1015 [M+NH4+]. 
3-((4-Fluorophenyl)thio)-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide (18). Yield; 45 
% 
1H NMR (CDCl3) δ 8.36 (s, 1H, NH), 8.02 (d, J = 1.5 Hz, 1H, ArH), 7.98-7.95 (m, 2H, ArH), 7.38-7.33 (m, 
2H, ArH), 6.99-6.94 (m, 2H, ArH), 3.27 (dd, J = 8.5, 13.5 Hz, 1H, CH2), 3.03 (dd, J = 5, 13.5 Hz,1H, CH2), 
2.72-2.64 (m, 1H, CH), 1.36 (d, J = 6.5 Hz, 3H, CH3); 19F NMR (CDCl3) δ -60.14, -114.70; 
13C NMR (CDCl3) 
δ 173.99 (C=O), 161.95 (d, 1JC-F = 245.8 Hz, ArC), 142.68 (ArC), 142.36 (ArC), 132.52 (d, 3JC-F = 7.8 Hz, 
ArCH), 130.12 (d, 4JC-F = 2.9 Hz, ArC), 127.12 (ArCH), 125.15 (q, 2JC-F = 34.3 Hz, ArC), 122.23 (ArCH), 
121.74 (q, 1JC-F = 271.9 Hz, CF3), 118.16 (q, 3JC-F = 6.1 Hz, ArCH), 116.23 (d, 2JC-F = 21.9 Hz, ArCH), 42.56 
(CH), 38.42 (CH2), 17.72 (CH3). MS [ESI, m/z]: HRMS calcd for C17H14F4N2O3S [M+H], 403.0739; found, 
403.0746. 
2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-((4-(trifluoromethyl)phenyl)thio)propanamide 
(19). Yield; 52 % 
1H NMR (CDCl3) δ 8.00-7.92 (m, 3H, ArH), 7.74 (s, 1H, NH), 7.53 (d, J = 8 Hz, 2H, ArH), 7.41 (d, J = 8 Hz, 
2H, ArH), 3.27 (dd, J = 9, 13.5 Hz, 1H, CH2), 3.16 (dd, J = 5, 14 Hz,1H, CH2), 2.75-2.67 (m, 1H, CH), 1.44 
(d, J = 7 Hz, 3H, CH3); 19F NMR (CDCl3) δ -60.13, -62.56; 
13C NMR (CDCl3) δ 173.16 (C=O), 143.13 (ArC), 
141.71 (ArC), 140.58 (ArC), 128.25 (q, 2JC-F = 32.6 Hz, ArC), 127.94 (ArCH), 127.10 (ArCH), 125.95 (q, 3JC-
F = 3.8 Hz, ArCH), 125.30 (q, 2JC-F = 33.9 Hz, ArC), 122.13 (ArCH), 123.90 (q, 1JC-F = 270.3 Hz, CF3), 121.66 
(q, 1JC-F = 272.4 Hz, CF3), 118.22 (q, 3JC-F = 6 Hz, ArCH), 42.73 (CH), 35.92 (CH2), 17.90 (CH3). MS [ESI, 
m/z]: HRMS calcd for C18H14F6N2O3S [M+H], 453.0702; found, 453.0699. 
3-((3,5-Bis(trifluoromethyl)phenyl)thio)-N-(4-cyano-2-(trifluoromethyl)phenyl)-2-methyl 
propanamide (23). Yield; 41 % 
1H NMR (CDCl3) δ 8.54 (d, J = 9 Hz, 1H, ArH), 7.92 (d, J= 1.5 Hz, 1H, ArH), 7.84 (dd, J= 2, 9 Hz, 1H, ArH), 
7.75 (s, 1H, ArH), 7.70 (s, 1H, NH), 7.67 (s, 1H, ArH), 3.47 (dd, J= 8.5, 13.5 Hz, 1H, CH2), 3.19 (dd, J= 5.5, 
13.5 Hz, 1H, CH2), 2.77-2.69 (m, 1H, , CH), 1.45 (d, J = 7 Hz, 3H, CH3); 19F NMR (CDCl3) δ -61.15, -63.10; 
13C NMR (CDCl3) δ 172.43 (C=O), 139.27 (ArC), 138.79 (ArC), 136.69 (ArCH), 132.34 (q, 2JC-F = 33.3 Hz, 
ArC), 130.25 (q, 3JC-F = 5.4 Hz, ArCH), 128.38 (q, 3JC-F = 3.3 Hz, ArCH), 123.64 (ArCH), 122.89 (q, 1JC-F = 
271.9 Hz, CF3), 122.24 (ArC), 118.64 (q, 1JC-F = 304 Hz, CF3), 120.01 (sept, 3JC-F = 3.8 Hz, ArCH), 117.43 
(CN), 108.08 (ArC), 43.06 (CH), 36.62 (CH2), 17.63 (CH3). C20H13F9N2OS, MS (ES+) m/z: 523.0491 
[M+Na+], 518.0943 [M+NH4+]. 
3-((4-Fluorophenyl)thio)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)propanamide (24). Yield; 49 
% 
1H NMR (CDCl3) δ 8.65 (d, J = 9 Hz, 1H, ArH), 8.52 (d, J = 2 Hz, 1H, ArH), 8.42 (dd, J= 2, 9 Hz, 1H, ArH), 
7.84 (s, 1H, NH), 7.40 (dd, J = 5.5, 8.5 Hz, 2H, ArH), 7.01 (t, J = 8.5 Hz, 2H, ArH), 3.28 (dd, J = 8.5, 14 Hz, 
1H, CH2), 3.28 (dd, J = 5, 13.5 Hz, 1H, CH2), 2.65 (sext, J = 7 Hz, 1H, CH), 1.38 (d, J = 7 Hz, 3H, CH3); 19F 
NMR (CDCl3) δ -61.03, -114.95; 
13C NMR (CDCl3) δ 173.15 (C=O), 162.14 (d, 1JC-F = 245.8 Hz, ArC), 142.89 
(ArC), 140.76 (ArC), 133.03 (d, 3JC-F = 8 Hz, ArCH), 129.83 (d, 4JC-F = 3.4 Hz, ArC),  128.26 (ArCH), 123.36 
(ArCH), 122.89 (q, 1JC-F = 272.1 Hz, CF3), 122.32 (q, 3JC-F = 6 Hz, ArCH), 119.14 (q, 2JC-F = 31 Hz, ArC), 
116.36 (d, 2JC-F = 22 Hz, ArCH), 43.05 (CH), 38.76 (CH2), 17.41 (CH3). MS [ESI, m/z]: HRMS calcd for 
C17H14F4N2O3S [M+H], 403.0734; found, 403.0733. 
2-Methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-((4-(trifluoromethyl)phenyl)thio)propanamide 
(25). Yield; 56 % 
1H NMR (CDCl3) δ 8.62 (d, J = 9 Hz, 1H, ArH), 8.52 (d, J = 2.5 Hz, 1H, ArH), 8.47 (dd, J= 2.5, 9 Hz, 1H, ArH), 
7.81 (s, 1H, NH), 7.54 (d, J = 8 Hz, 2H, ArH), 7.43 (d, J = 8 Hz, 2H, ArH), 3.42 (dd, J = 8.5, 13.5 Hz, 1H, 
CH2), 3.16 (dd, J = 5.5, 14 Hz, 1H, CH2), 2.74 (sextet of triplet, J = 7, 1.5 Hz, 1H, CH), 1.44 (d, J = 7 Hz, 3H, 
CH3); 19F NMR (CDCl3) δ -61.05, -62.58; 13C NMR (CDCl3) δ 172.84 (C=O), 140.58 (ArC), 140.49 (ArC), 
128.36 (ArCH), 128.29 (q, 2JC-F = 32.5 Hz, ArC), 128.25 (ArCH), 125.91 (q, 3JC-F = 3.6 Hz, ArCH), 123.94 (q, 
1JC-F = 270 Hz, CF3), 122.85 (q, 1JC-F = 271.8 Hz, CF3), 122.31 (q, 3JC-F = 5.6 Hz, ArCH), 119.25 (q, 2JC-F = 31.5 
Hz, ArC), 43.03 (CH), 36.18 (CH2), 17.51 (CH3). MS [ESI, m/z]: HRMS calcd for C18H14F6N2O3S [M+H], 
453.0708; found, 453.0711. 
3-((3,5-Bis(trifluoromethyl)phenyl)thio)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl) 
propanamide (26). Yield; 24% 
1H NMR (CDCl3) δ 8.64 (d, J = 9.5 Hz, 1H, ArH), 8.54 (d, J = 3 Hz, 1H, ArH), 8.43 (dd, J= 2.5, 9.5 Hz, 1H, 
ArH), 7.79 (s, 1H, NH), 7.76 (s, 2H, ArH), 7.01 (s, 1H, ArH), 3.48 (dd, J = 8, 13.5 Hz, 1H, CH2), 3.21 (dd, J 
= 5.5, 13.5 Hz, 1H, CH2), 2.76 (sextet of triplet, J = 7, 1.5 Hz, 1H, CH), 1.47 (d, J = 7 Hz, 3H, CH3); 19F NMR 
(CDCl3) δ -61.10, -63.11; 
13C NMR (CDCl3) δ 172.47 (C=O), 143.09 (ArC), 140.41 (ArC), 139.21 (ArC), 
132.38 (q, 2JC-F = 33.3 Hz, ArC), 128.40 (d, 4JC-F = 3.3 Hz, ArCH), 128.31 (ArCH), 123.30 (ArCH), 122.87 (q, 
1JC-F = 271.1 Hz, CF3), 122.85 (q, 1JC-F = 271.9 Hz, CF3), 122.34 (q, 3JC-F = 5.9 Hz, ArCH), 119.30 (q, 2JC-F = 
31.1 Hz, ArC), 120.06 (sept, 3JC-F = 3.6 Hz, ArCH), 43.13 (CH), 36.62 (CH2), 17.63 (CH3). MS [ESI, m/z]: 
HRMS calcd for C19H13F9N2O3S [M+H], 521.0573; found, 521.0576. 
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-2,3-bis((4-(trifluoromethyl)phenyl)thio) 
propanamide (27). Yield; 42% 
1H-NMR: (CDCl3) δ 9.06 (s, 1H, NH), 7.97 (d, J = 2Hz, 1H ArH), 7.85 (dd, J = 2, 8.5Hz, 1H, Ar-H), 7.79 (d, J 
= 8.5Hz, 1H, ArH), 7.59 (d, J = 8.5Hz, 2H, ArH), 7.51 (d, J = 8Hz, 2H, ArH), 7.44 (dd, J = 8.5, 13.5Hz, 4H, 
ArH), 3.60 (d, J = 13.5Hz, 1H, CH2), 3.52 (d, J = 13.5Hz, 1H, CH2), 1.73 (s, 3H, CH3). 19F-NMR: (CDCl3) δ -
62.23, -62.65, -63.00. 13C-NMR: (CDCl3) δ 170.74 (C=O), 141.22 (ArC), 140.60 (ArC), 135.86 (ArCH), 
134.35 (ArCH), 134.23 (ArC), 134.11 (q, 2JC-F = 31Hz, ArC), 131.69 (q, 2JC-F = 33.1Hz, ArC), 131.26 (ArCH), 
129.00 (ArCH), 128.64 (q, 2JC-F = 32.6Hz, ArC), 126.35 (q, 3JC-F = 3.6Hz, ArCH), 125.89 – 125.74 (m, ArCH), 
123.77 (q, 1JC-F = 270Hz, CF3), 123.51 (q, 1JC-F = 270.8Hz, CF3), 122.00 (q, 1JC-F = 272.3Hz, CF3), 117.14 (q, 
3JC-F = 5Hz, ArCH), 115.30 (CN), 105.04 (ArC), 59.51 (-C-CH3), 42.06 (CH2), 23.87 (CH3). HRMS calcd for 
C26H17F9N2OS2, 609.0711; found, 609.0708 [M+H], 626.0965 [M+NH4+]. 
2,3-Bis((3,5-bis(trifluoromethyl)phenyl)thio)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl) 
propanamide (28). Yield; 48 % 
1H NMR (CDCl3) δ 9.19 (s, 1H, NH), 8.59 (d, J = 3 Hz, 1H, ArH), 8.54 (d, J = 9.5 Hz, 1H, ArH), 8.45 (dd, J= 
2.5, 9 Hz, 1H, ArH), 7.92 (s, 1H, ArH), 7.89 (s, 2H, ArH), 7.78 (s, 2H, ArH), 7.67 (s, 1H, ArH), 3.63 (d, J = 
13.5 Hz, 1H, CH2), 3.49 (d, J = 13.5 Hz, 1H, CH2), 1.80 (s, 3H, CH3); 19F NMR (CDCl3) δ -61.05, -63.14, 
63.19; 13C NMR (CDCl3) δ 169.75 (C=O), 143.34 (ArC), 139.89 (ArC), 138.78 (ArC), 132.30 (ArC), 132.87 
(q, 2JC-F = 33.9 Hz, ArC), 132.42 (q, 2JC-F = 33.3 Hz, ArC), 134.69, 134.66 (ArCH), 129.58 (d, 3JC-F = 3.6 Hz, 
ArCH), 128.53 (ArCH), 122.44 (q, 1JC-F = 271.6 Hz, CF3), 123.87 (septet, 3JC-F = 3.6 Hz, ArCH), 122.53 (q, 
3JC-F = 5.5 Hz, ArCH), 122.88 (q, 1JC-F = 272.3 Hz, CF3), 122.75 (q, 1JC-F = 274.4 Hz, CF3), 122.31 (ArCH), 
120.72 (septet, 3JC-F = 3.9 Hz, ArCH), 119.29 (q, 2JC-F = 31.5 Hz, ArC), 57.94 (CH3C), 42.43 (CH2), 14.15 
(CH3). MS [ESI, m/z]: HRMS for C27H15F15N2O3S2 [M+H], 765.0371. 
4.1.3 General method for the preparation of sulfones derivatives 29-41 
To a stirring solution of the corresponding sulfide 14-26 (0.7 mmol) in 5 mL anhydrous 
dichloromethane, was added 3-chloroperbenzoic acid (MCPBA) (1.4 mmol). The solution was stirred at 
room temperature for 24 h. The reaction mixture was neutralized with 1M sodium hydroxide. 50 mL 
distilled water was added to the reaction mixture and was extracted with 2 x 50mL of dichloromethane. 
The combined organic layers were washed, dried over anhydrous sodium sulfate, and concentrated in 
vacuo. The crude residue was purified by column chromatography, preparative TLC or crystallization 
from methanol. 
N-(4-cyano-3-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-methylpropanamide (29). 
Yield; 69% 
1H-NMR: ((CD3)2SO) δ 10.82 (s, 1H, NH), 8.12 (d, J = 2Hz, 1H, ArH), 8.09 (d, J = 8.5Hz, 1H, ArH), 7.94 (dd, 
J = 5, 9Hz, 2H, ArH), 7.82 (dd, J = 2, 8Hz, 1H, ArH), 7.38 (t, J = 9Hz, 2H, ArH), 3.81 (dd, J = 9.5, 14.5Hz, 
1H, CH2), 3.50 (dd, J = 4, 14.5Hz, 1H, CH2), 3.06 – 2.98 (m, 1H, CH), 1.23 (d, J = 7.5Hz, 3H, CH3). 19F-NMR: 
((CD3)2SO) δ -61.34, -104.87, 
13C NMR ((CD3)2SO) δ 173.24 (C=O), 165.56 (d, 1JC-F = 250 Hz, ArC), 143.76 
(ArC), 136.92 (ArCH), 135.71 (ArC), 132.13 (q, 2JC-F = 31.5 Hz, ArC), 131.61 (d, 3JC-F = 9.9 Hz, ArCH), 122.86 
(q, 1JC-F = 273.3 Hz, CF3), 122.49 (ArCH), 116.93 (d, 2JC-F = 22.6 Hz, ArCH), 116.84 (m, ArCH), 116.21 (CN), 
102.26 (ArC), 57.72 (CH2), 36.81 (CH), 18.76 (CH3). HRMS calcd for C18H14F4N2O3S [M+H], 415.0734; 
found, 415.0735, [M+NH4+], 432.0999. 
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-3-((4-(trifluoromethyl)phenyl)sulfonyl) 
propanamide (30). Yield; 21% 
1H-NMR: (CDCl3) δ 8.88 (s, 1H, NH), 8.12 (d, J = 8.5Hz, 2H ArH), 7.96 (d, J = 2Hz, 1H, ArH), 7.88 – 7.83 
(m, 3H, ArH), 7.72 (d, J = 8.5Hz, 1H, ArH), 3.99 (dd, J = 9.5, 14Hz, 1H, CH2), 3.43 – 3.35 (m, 1H, CH), 3.22 
(dd, J = 3, 14Hz, 1H, CH2), 1.43 (d, J = 7.5Hz, 3H, CH3). 19F-NMR: (CDCl3) δ -62.31, -63.42. 13C-NMR: 
(CDCl3) δ 172.27 (C=O), 142.37 (ArC), 142.25 (ArC), 136.04 (q, 2JC-F = 33Hz, ArC), 135.75 (ArCH), 133.72 
(q, 2JC-F = 32.5Hz, ArC), 128.65 (ArCH), 126.67 (q, 3JC-F = 3.6Hz, ArCH), 122.87 (q, 1JC-F = 271.6Hz, CF3), 
122.07 (q, 1JC-F = 272.5Hz, CF3), 121.81 (ArCH), 117.18 (q, 3JC-F = 4.9Hz, ArCH), 115.52 (CN), 104.40 (ArC), 
58.88 (-CH2), 36.69 (CH), 18.88 (CH3). HRMS calculated for C19H14F6N2O3S [M+H], 465.0708; found, 
465.0703. 
3-((3,5-Bis(trifluoromethyl)phenyl)sulfonyl)-N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl 
propanamide (31). Yield; 19% 
1H-NMR: (CDCl3) δ 8.38 (s, 1H, NH), 8.30 (s, 2H, ArH), 8.06 (s, 1H, ArH), 7.88 (d, J = 2Hz, 1H, ArH), 7.74 
(dd, J = 2, 8.5Hz, 1H, ArH), 7.68 (d, J = 8.5Hz, 1H, ArH), 3.91 (dd, J = 9.5, 14.5Hz, 1H, CH2), 3.29 – 3.21 
(m, 1H, CH), 3.17 (dd, J = 3.5, 14.5Hz, 1H, CH2), 1.37 (d, J = 7Hz, 3H, CH3). 19F-NMR: (CDCl3) δ -62.38, -
63.04. 13C-NMR: (CDCl3) δ 171.78 (C=O), 141.89 (ArC), 141.81 (ArC), 135.82 (ArCH), 134.03 (q, 2JC-F = 
32.6Hz, ArC), 133.43 (q, 2JC-F = 34.6Hz, ArC), 128.43 (q, 3JC-F = 3Hz, ArCH), 128.01 – 127.77 (m, ArCH), 
122.14 (q, 1JC-F = 271.8Hz, CF3), 122.00 (q, 1JC-F = 272.4Hz, CF3), 121.79 (ArCH), 117.23 (q, 3JC-F = 4.6Hz, 
ArCH), 115.52 (CN), 104.40 (ArC), 58.88 (CH2), 36.69 (CH), 18.88 (CH3). HRMS calculated for 
C20H13F9N2O3S [M+H], 533.0576; found, 533.0572. 
N-(4-cyano-3-(trifluoromethyl)phenyl)-2-methyl-3-((3-(trifluoromethoxy)phenyl)sulfonyl) 
propanamide (32). Yield; 95% 
1H-NMR: (CDCl3) δ 8.67 (s, 1H, NH), 7.88 (d, J = 2Hz, 1H, ArH), 7.82 (d, J = 7.5Hz, 1H, ArH), 7.77 (dd, J = 
2, 8.5Hz, 1H, ArH), 7.72 (s, 1H, ArH), 7.63 (d, J = 8.5Hz, 1H, ArH), 7.57 (t, J = 8Hz, 1H, ArH), 7.45 (d, J 
=8.5Hz, 1H, ArH), 3.86 (dd, J = 9.5, 14Hz, 1H, CH2), 3.34 – 3.25 (m, 1H, CH), 3.12 (dd, J = 3.5, 14.5Hz, 1H, 
CH2), 1.34 (d, J = 7Hz, 3H, CH3). 19F-NMR: (CDCl3) δ -58.04, -62.34. 13C-NMR: (CDCl3) δ 171.69 (C=O), 
149.10 (ArC), 141.72 (ArC), 140.37 (ArC), 135.21 (ArCH), 133.28 (q, 2JC-F = 32.8Hz, ArC), 130.95 (ArCH), 
126.19 (ArCH), 125.65 (ArCH), 121.55 (q, 1JC-F = 272.3Hz, OCF3), 121.30 (ArCH), 119.92 (ArCH), 119.68 
(q, 1JC-F = 258.3Hz, CF3), 116.76 (q, 3JC-F = 4.8Hz, ArCH), 115.05 (CN), 103.58 (ArC), 58.43 (CH2), 35.82 (-
CH), 18.46 (CH3). HRMS calculated for C19H14F6N2O4S [M+H], 481.0657; found, 481.0654. 
3-((4-Fluorophenyl)sulfonyl)-2-methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)propanamide (33). 
Yield; 41 % 
1H NMR (CD3OD) δ 8.14 (d, J = 2 Hz, 1H, ArH), 8.14 (d, J = 2 Hz, 1H, ArH), 8.01-7.97 (m, 2H, ArH), 7.88 
(dd, J = 2, 9 Hz, 1H, ArH), 7.32-7.26 (m, 2H, ArH), 3.91 (dd, J = 9.5, 14.5 Hz, 1H, CH2), 3.34 (dd, J = 3, 14.5 
Hz, 1H, CH2), 3.17-3.08 (m, 1H, CH), 1.34 (d, J = 7.5 Hz, 3H, CH3); 19F NMR (CD3OD) δ -61.67, -105.84; 
13C 
NMR (CD3OD) δ 175.65 (C=O), 168.31 (d, 1JC-F = 253.5 Hz, ArC), 145.40 (ArC), 145.01 (ArC), 137.66 (d, 
4JC-F = 3.3 Hz, ArC), 133.52 (d, 3JC-F = 9.9 Hz, ArCH), 129.05 (ArCH), 126.38 (q, 2JC-F = 33.5 Hz, ArC), 124.53 
(ArCH), 124.46 (q, 1JC-F = 270.9 Hz, CF3), 119.95 (q, 3JC-F = 5.8 Hz, ArCH), 118.53 (d, 2JC-F = 23.3 Hz, ArCH), 
60.25 (CH2), 39.09 (CH), 20.14 (CH3). MS [ESI, m/z]: HRMS calcd for C17H14F4N2O5S [M+H], 435.0638; 
found, 435.0643. 
2-Methyl-N-(4-nitro-3-(trifluoromethyl)phenyl)-3-((4-(trifluoromethyl)phenyl)sulfonyl) 
propanamide (34). Yield; 78 % 
1H NMR (CDCl3) δ 8.77 (s, 1H, NH), 8.15-8.11 (m, 3H, ArH), 7.96 (dd, J = 9, 2.5 Hz, 1H, ArH), 7.94-7.91 
(m, 1H, ArH), 7.90-7.87 (m, 2H, ArH), 3.97 (dd, J = 9.5, 14 Hz, 1H, CH2), 3.45-3.35 (m, 1H, CH), 3.22 (dd, 
J = 3, 14 Hz,1H, CH2), 1.45 (d, J = 7 Hz, 3H, CH3); 19F NMR (CDCl3) δ -60.18, -63.35; 
13C NMR (CDCl3) δ 
172.02 (C=O), 143.06 (ArC), 142.22 (ArC), 141.96 (ArC), 136.20 (q, 2JC-F = 33.3 Hz, ArC), 128.58 (ArCH), 
127.02 (ArCH), 126.79 (q, 3JC-F = 3.6 Hz, ArCH), 125.15 (q, 2JC-F = 33.8 Hz, ArC), 122.87 (q, 1JC-F = 271.4 
Hz, CF3), 122.12 (ArCH), 121.65 (q, 1JC-F = 271.9 Hz, CF3), 118.22 (q, 3JC-F = 5.6 Hz, ArCH), 58.98 (CH2), 
36.22 (CH), 18.94 (CH3). MS [ESI, m/z]: HRMS calcd for C18H14F6N2O5S [M+NH4], 502.0866; found, 
502.0857. 
3-((3,5-Bis(trifluoromethyl)phenyl)sulfonyl)-2-methyl-N-(4-nitro-3-(trifluoromethyl) phenyl) 
propanamide (35). Yield; 69% 
1H NMR (CD3OD) δ 8.48 (s, 2H, ArH), 8.25 (s, 1H, ArH), 8.04 (d, J = 1.5 Hz, ArH), 8.01 (d, J = 9 Hz, 1H, 
ArH), 7.78 (dd, J = 1.5, 9 Hz, 1H, ArH),  4.13 (dd, J = 10.5, 15 Hz, 1H, CH2), 3.51 (dd, J = 3, 15 Hz, 1H, CH2), 
3.23-3.15 (m, 1H, CH), 1.36 (d, J = 7 Hz, 3H, CH3); 19F NMR (CD3OD) δ -61.79, -64.50; 
13C NMR (CD3OD) 
δ 172.90 (C=O), 142.79 (ArC), 142.71 (ArC), 142.01 (ArC), 132.65 (q, 2JC-F = 38.8 Hz, ArC), 128.44 (q, 3JC-
F = 3Hz, ArCH), 127.44 (q, 3JC-F = 3 Hz ArCH), 126.67 (ArCH), 125.58 (m, ArC), 124.31 (m, ArC), 123.33 (q, 
1JC-F = 270.3 Hz, CF3), 122.01 (ArCH), 121.9 (q, 1JC-F = 270.9 Hz, CF3), 117.68 (m, ArCH), 57.70 (CH2), 36.74 
(CH), 18.23 (CH3). MS [ESI, m/z]: HRMS calcd for C19H13F9N2O5S [M+NH4], 570.0740; found, 570.0733. 
N-(4-cyano-2-(trifluoromethyl)phenyl)-3-((4-fluorophenyl)sulfonyl)-2-methylpropanamide (36). 
Yield; 68 % 
1H NMR (CDCl3) δ 8.41 (d, J = 8.5 Hz, 1H, ArH), 8.00-7.95 (m, 3H, ArH), 7.86 (dd, J= 1.5, 8.5 Hz, 1H, ArH), 
7.83 (s, 1H, NH), 7.28-7.24 (m, 2H, ArH), 3.85-3.79 (m, 1H, CH2), 3.21-3.14 (m, 2H, CH, CH2), 1.45 (d, J = 
7 Hz, 3H, CH3); 19F NMR (CDCl3) δ -61.04, -102.36; 
13C NMR (CDCl3) δ 171.66 (C=O), 166.08 (d, 1JC-F = 
256.3 Hz, ArC), 138.82 (ArC), 136.59 (ArCH), 135.19 (ArC), 135.16 (ArC), 130.89 (d, 3JC-F = 9.4 Hz, ArCH), 
130.28 (q, 3JC-F = 5.5 Hz, ArCH), 124.51 (ArCH), 122.84 (q, 1JC-F = 271.6 Hz, CF3), 117.25 (CN), 116.88 (d, 
2JC-F = 22.6 Hz, ArCH), 108.42 (ArC), 58.99 (CH2), 37.06 (CH), 18.50 (CH3). MS [ESI, m/z]: HRMS calcd for 
C18H14F4N2O3S [M+H], 415.0734; found, 415.0733. 
N-(4-cyano-2-(trifluoromethyl)phenyl)-2-methyl-3-((4-(trifluoromethyl)phenyl)sulfonyl) 
propanamide (37). Yield; 71 % 
1H NMR (CD3OD) δ 8.20 (d, J = 8 Hz, 2H, ArH), 8.16 (d, J = 2 Hz, 1H, ArH), 8.02-7.99 (m, 3H, ArH), 7.76 
(d, J= 8.5 Hz, 1H, ArH), 3.92 (dd, J = 9.5, 14 Hz, 1H, CH2), 3.43 (dd, J = 3.5, 14.5 Hz, 1H, CH2), 3.32-3.25 
(m, 1H, CH), 1.34 (d, J = 7 Hz, 3H, CH3); 19F NMR (CD3OD) δ -62.52, -64.66; 
13C NMR (CD3OD) δ 173.92 
(C=O), 143.13 (ArC), 139.04 (q, 3JC-F = 1.5 Hz ArC), 136.03 (ArCH), 134.96 (q, 2JC-F = 32.9 Hz, ArC), 130.44 
(q, 3JC-F = 5.4 Hz, ArCH), 129.84 (ArCH), 128.85 (ArCH), 126.31 (q, 3JC-F = 3.8 Hz, ArCH), 125.35 (q, 2JC-F = 
30.8 Hz, ArC), 123.39 (q, 1JC-F = 270.9 Hz, CF3), 122.61 (q, 1JC-F = 271.6 Hz, CF3), 116.82 (CN), 110.13 (ArC), 
57.47 (CH2), 35.43 (CH), 17.56 (CH3). MS [ESI, m/z]: HRMS calcd for C19H14F6N2O3S [M+H], 465.0702; 
found, 465.0699. 
3-((3,5-Bis(trifluoromethyl)phenyl)sulfonyl)-N-(4-cyano-2-(trifluoromethyl)phenyl)-2-methyl 
propanamide (38). Yield; 59 % 
1H NMR (CDCl3) δ 8.40 (s, 1H, ArH), 8.38 (d, J= 9 Hz, 1H, ArH), 8.18 (s, 1H, ArH), 7.96 (s, 1H, ArH), 7.86 
(d, J= 9 Hz, 1H, ArH), 7.81 (s, 1H, NH), 3.47 (dd, J= 10, 15 Hz, 1H, CH2), 3.31-3.23 (m, 2H, CH2, CH), 1.50 
(d, J = 7 Hz, 3H, CH3); 19F NMR (CDCl3) δ -61.04, -62.95; 
13C NMR (CDCl3) 
13C NMR (CDCl3-d1) δ 171.21 
(C=O), 142.14 (ArC), 138.55 (ArC), 136.65 (ArCH), 133.40 (q, 2JC-F = 35 Hz, ArC), 132.32 (q, 3JC-F = 5.5 Hz, 
ArCH), 128.44 (q, 3JC-F = 3.4 Hz, ArCH), 127.81 (sept, 3JC-F = 3.8 Hz, ArCH), 124.27 (ArCH), 122.84 (q, 1JC-F 
= 271.8 Hz, CF3), 122.66 (ArC), 117.56 (q, 1JC-F = 281.5 Hz, CF3), , 117.16 (CN), 108.64 (ArC), 58.77 (CH2), 
37.12 (CH), 18.56 (CH3).  MS (ES+) m/z:  C20H13F9N2O3S, 550.084 [M+NH4+], 555.0395 [M+Na+]. 
3-((4-Fluorophenyl)sulfonyl)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)propanamide (39). 
Yield; 72 % 
1H NMR (CDCl3) δ 8.53 (d, J = 2 Hz, 1H, ArH), 8.44-8.39 (m, 2H, ArH), 8.04 (s, 1H, NH), 7.97 (dd, J= 5, 9 
Hz, 2H, ArH), 7.25 (t, J = 8.5 Hz, 2H, ArH), 3.84 (dd, J = 8.5, 14 Hz, 1H, CH2), 3.30-3.22 (m, 1H, CH), 3.17 
(dd, J = 4, 14 Hz, 1H, CH2), 1.44 (d, J = 7.5 Hz, 3H, CH3); 19F NMR (CDCl3) δ -60.99, -102.41; 
13C NMR 
(CDCl3) δ 170.91 (C=O), 165.02 (d, 1JC-F = 255 Hz, ArC), 143.40 (ArC), 140.49 (ArC), 135.13 (d, 4JC-F = 3 Hz, 
ArC), 130.89 (d, 3JC-F = 9.9 Hz, ArCH), 128.05 (ArCH), 124.67 (ArCH), 122.73 (q, 1JC-F = 271.9 Hz, CF3), 
122.33 (q, 3JC-F = 5.8 Hz, ArCH), 120.50 (q, 2JC-F = 31.1 Hz, ArC), 116.86 (d, 2JC-F = 22.6 Hz, ArCH), 58.21 
(CH2), 36.88 (CH), 18.53 (CH3). HRMS calcd for C17H14F4N2O5S [M+H], 435.0632; found, 435.0631. 
2-Methyl-N-(4-nitro-2-(trifluoromethyl)phenyl)-3-((4-(trifluoromethyl)phenyl)sulfonyl) 
propanamide (40). Yield; 74 % 
1H NMR (CDCl3) δ 8.56 (d, J = 2Hz, 1H, ArH), 8.48-8.40 (m, 2H, ArH), 8.10 (d, J= 8.5 Hz, 2H, ArH), 7.91 -
7.84 (m, 2H, ArH, 1H, NH), 3.89 (dd, J = 9.5, 15 Hz, 1H, CH2), 3.26-3.16 (m, 1H, CH2, 1H, CH), 1.48 (d, J = 
7 Hz, 3H, CH3); 19F NMR (CDCl3) δ -60.93, 60.97, -63.28; 13C NMR (CDCl3) δ 171.51 (C=O), 143.41 (ArC), 
142.58 (ArC), 140.32 (ArC), 135.88 (q, 2JC-F = 32.9 Hz, ArC), 128.70 (ArCH), 128.19 (ArCH), 126.64 (q, 3JC-
F = 3.6 Hz, ArCH), 124.15 (ArCH), 122.95 (q, 1JC-F = 271.8 Hz, CF3), 122.79 (q, 1JC-F = 271.9 Hz, CF3), 122.36 
(q, 3JC-F = 5.5 Hz, ArCH), 120.12 (q, 2JC-F = 30.9 Hz, ArC), 58.67 (CH), 37.08 (CH2), 18.57 (CH3). MS [ESI, 
m/z]: HRMS calcd for C18H14F6N2O5S [M+H], 485.0600; found, 485.0595. 
3-((3,5-Bis(trifluoromethyl)phenyl)sulfonyl)-2-methyl-N-(4-nitro-2-(trifluoromethyl)phenyl) 
propanamide (41). Yield; 58 %. 
1H NMR ((CD3)2SO) δ 10.10 (s, 1H, NH), 8.65 (s, 1H, ArH), 8.55 (s, 2H, ArH), 8.52 (d, J = 8.5 Hz, 1H, ArH), 
8.46 (d, J = 2 Hz, 1H, ArH), 7.72 (d, J = 8.5 Hz, 1H, ArH), 4.01 (dd, J = 9, 14.5 Hz, 1H, CH2), 3.84 (dd, J = 3, 
14 Hz, 1H, CH2), 3.34 (m, 1H, CH), 1.26 (d, J = 7 Hz, 3H, CH3); 19F NMR ((CD3)2SO) δ -59.84, -61.32; 
13C 
NMR ((CD3)2SO) δ 173.28 (C=O), 144.86 (ArC), 142.40 (ArC), 141.27 (ArC), 131.92 (q, 2JC-F = 34 Hz, ArC), 
130.21 (ArCH), 129.29 (d, 4JC-F = 3.4 Hz, ArCH), 128.65 (m, ArCH), 128.33 (ArCH), 124.06 (q, 2JC-F = 31.4 
Hz, ArC), 122.79 (q, 1JC-F = 275.3 Hz, CF3), 123.01 (q, 1JC-F = 271.8 Hz, CF3), 122.68 (q, 3JC-F = 5.5 Hz, ArCH), 
56.86 (CH2), 35.22 (CH), 18.70 (CH3). MS [ESI, m/z]: HRMS calcd for C19H13F9N2O5S [M+NH4], 570.0740; 
found, 570.0736. 
 
4.2 In vitro cell based assay 
4.2.1 Cell culture  
All cells were cultured in T75 flasks in a humidified atmosphere of 5% CO2 at 37°C. LNCaP cells were 
cultured in RPMI-1640 medium, PC3 and VCaP cells in DMEM, all supplemented with 10% FCS and 
antibiotics (penicillin 100U/ml and streptomycin 100μg).  
4.2.2 Anti-androgen treatment in vitro  
Bicalutamide and enzalutamide were used as positive controls (used as the clinical standard) in LNCaP, 
PC3 and VCaP cells, and DMSO was used as a vehicle control. Nine 1⁄2 serial dilutions of 10 mM 
bicalutamide stock were made in 50 μL of DMSO to give nine increasing concentrations from 0.1 μM 
to 100 μM. All novel deshydroxy compounds were tested in LNCaP cells, and compounds 27, 28 and 33 
were subsequently tested in PC3 and VCaP cells because of their low IC50 values.  
PC3 and LNCaP cells were plated in a 96- well plate (4000cells/well) and then incubated overnight to 
adhere. Each drug concentration (0-100uM) was then added in sequence to ten tubes of fresh media 
to achieve a 1:100 dilution. The old medium was then gently removed and replaced with 200 μL of 
fresh media containing the nine increasing drug concentrations and the DMSO control, in triplicate. 
Following 96 hours of incubation the samples were tested with the MTT or MTS assay. The IC50 was 
then calculated from the mean of these triplicate values and dose-response curves were plotted. VCaP 
cells were treated as above, with the following exceptions. The novel compounds were diluted 1:50, 
only 100 μL of the old medium was extracted and it was replaced with 100 μL of the novel compound 
in media. This was done to avoid removing the cells from the 96-well plates in view of their poor 
adherence.  
4.2.3 MTT and MTS assays  
Colorimetric MTT (LNCaP and PC3) and MTS (VCaP) assays were used to determine cell viability 
following in vitro anti-androgen treatment. 20μL (1/10th well volume) of MTT or MTS were added to 
the wells as appropriate. MTS absorbance was recorded at 490 nm by the Elx800TM microplate reader 
after 1 and 2-hours of incubation. For the MTT assay, following the appearance of purple formazan 
crystals under the light microscope, the medium was then carefully removed and the formazan crystals 
dissolved in 200 μL of acidified isopropanol and MTT absorbance was recorded at 540nm on the 
Elx800TM microplate reader. Percentage cell viability was normalised to the DMSO control.  
4.2.4 Statistics  
Cell number-MTT correlations and IC50 values were calculated from the mean of three replicates using 
Microsoft Excel and GraphPad Prism v6.01 (GraphPad Software, Inc., San Diego, CA). Cell number-MTT 
correlations were analysed by linear regression, whereas IC50 values were produced through non-linear 
regression. qPCR results were analysed using the ΔΔCT method in Excel. Mean IC50 values were then 
analysed for statistical significance (p=<0.05) compared to bicalutamide and enzalutamide using 
GraphPad Prism v6.01 with consideration to the OECD guidelines. 
One-way analysis of variance (ANOVA) followed by Tukey’s Honest Significant Difference test analysed 
the dose-response data for compounds 27, 28 and 33 in LNCaP cells, which satisfied the assumptions 
of normality and homogeneity of variance according to the D'Agostino- Pearson omnibus, Brown-
Forsythe and Bartlett’s tests. The Kruskal-Wallis test followed by the Dunn’s test analysed the dose-
response data for compound 28 in LNCaP cells and compounds 27, 28 and 33 in PC3 cells. 
4.3 PSA Expression and androgen inhibition qPCR experiments  
LNCaP cells were trypsinised and re-suspended in 13ml of RPMI. 0.5ml of this cell suspension was then 
added to individual wells in 6-well plates with 3 ml of fresh RPMI, and the cells incubated for 24-hours 
to adhere. Two individual wells in each plate received no treatment and DMSO at a 1:100 dilution as 
negative controls. The 6-well plates used to analyse PSA expression by qPCR then were treated with 5, 
10, 50 and 100 μM of bicalutamide, compounds 27, 28 and 33, followed by 24-hours incubation.  
4.3.1 RNA Isolation  
RNA isolation was carried out in the six-well plates using the Sigma procedure. The media was gently 
removed, 1ml of TRI-reagent added per sample and the viscous lysate containing DNA, RNA and 
proteins transferred to 1.5ml Eppendorf tubes. 200μl of 1-bromo-3-chloropropane was then added, 
the Eppendorf tubes vortexed, left to stand for 5 minutes and stored at -80°C. The samples were then 
warmed to room temperature, vortexed and centrifuged at 12,000 x g for 15 minutes at 4°C to 
solubilise the RNA in the upper, colourless aqueous phase. The samples were then kept on ice, the 
aqueous phase transferred to fresh Eppendorf tubes and 0.5ml of isopropanol added. The tubes were 
then vortexed, left to stand for 5 minutes and centrifuged at 12,000 x g for 10 minutes at 4°C in order 
to recover the RNA pellet. After removing the supernatant, the pellet was washed with 1ml of 75% 
ethanol, vortexed and centrifuged at 7500 x g for 5 minutes at 4°C. After this, ethanol was carefully 
removed, the samples briefly air-dried for 5-10 minutes and the RNA pellet dissolved with 20μl of 
RNAse-free PCR water. The RNA concentration was then measured in ng/μl by recording the absorption 
of each 1μl sample at 260nm on the Implen NanoPhotometer against nuclease-free water as a control. 
The samples were then stored at -80°C for 24 hours.  
4.3.2 Complementary DNA synthesis (cDNA)  
The RNA samples were uniformly diluted to 50ng/μl on ice. 10 μl of RNA and 10 μl of RT mix were then 
centrally added to a 96-well non-skirted PCR plate on ice, thermosealed and centrifuged up to 1000rpm 
in the Grant bio LMC-3000. The components of the RT mix are shown below: The samples were then 
placed in the Simpli-Amp thermal cycler under the following conditions: 25°C for 5 minutes, 42°C for 
60 minutes, 70°C for 15 minutes, and 4°C. The samples were then stored at -20°C overnight.  
4.3.3 Quantitative polymerase chain reaction (qPCR)  
qPCR was performed in triplicate to analyse the LNCaP cells for relative PSA gene expression. The PSA 
primer was run alongside the AR, GAPDH, RPL19 and B-actin as housekeeping genes in order to 
normalise the data and validate the results. These forward and reverse primer pairs were briefly 
thawed and vortexed, diluted 1:40 with RNAse-free PCR water in four 1.5ml Eppendorf tubes, and 
returned to ice. Following this, the cDNA was diluted in 20μl of RNAse-free PCR water. 40ul of this 
diluted cDNA was then transferred into 0.5ml Eppendorf tubes and kept on ice. 2ul of this diluted cDNA 
was added to individual wells of an optical qPCR 96-well plate, followed by 8μl of the PCR mix. The 
qPCR plate was then thermosealed, centrifuged up to 1000rpm in the Grant bio LMC-3000, and loaded 
into the StepOnePlus real-time PCR system. The PCR reaction volume was 10μl, and 50 cycles were 
performed within the standard 2-hour cycle. 
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